We are pleased to welcome Marc S. Hulin, DVM, DACLAM to the Biomere team as the Global Head of Lab Animal Sciences!

“I look forward to leading the Biomere animal care and use program.

The ethical and responsible care of research animals within our program

is my personal vision and passion. This will be our primary focus. Healthy,

enriched animal models measure our success as an organization and assures

best outcomes for our clients.

The development and growth of our people will be the foundation of

our strategy. To this end, we will focus our energy on additional training

supporting technical profi ciency and operational effi ciency. We will continue

to deliver high quality results while ensuring the highest ethical standards

for our research animal partners.”

Marc is a board-certifi ed laboratory animal veterinarian with over twenty-seven

years of experience on teams in pharmaceutical and academic research.

He has broad experience with federal and state regulations and international

standards for accreditation pertaining to animal care and use programs

including AAALAC, International, CCAC, USDA, FDA and OLAW.

His experience, enthusiasm, and desire to support to our clients’ research

journeys made it clear that he would be the perfect addition to our team.

Welcome Marc!

No Patient Left Behind

Many of the world’s biggest companies and brightest minds are totally focused on a COVID-19 treatment – vaccine.

At Biomere, we are personally invested in your drug discovery efforts aimed at filling the drug development pipeline with new and innovative therapies.

Everyone has a role to play and we know ours. We are staying the course, focused on what we do best.

Leave no drug behind. Leave no patient behind.

No Drug Left Behind

We are personally invested in your efforts to continue the flow of therapies to those in need.

Some of the worlds’ best companies are totally focused on a treatment – vaccine.

Everyone has a role to play and we know where ours is. No less important, but not working on COVID-19. We are staying on course, focused on what we do best.

Leave no drug behind. Leave no patient behind.

COVID-19 Vaccine Receives Approval in China to Begin Human Trials

March 22, 2020 — A recombinant novel coronavirus vaccine candidate (Ad5-nCoV), developed by CanSino Biologics Inc. and China’s Academy of Military Medical Sciences, received Chinese regulatory approval to start human trials against COVID-19 on March 22, 2020.

Results from preclinical animal studies of Ad5-nCoV show that the vaccine candidate induces strong immune responses in animal models. Preclinical animal safety studies demonstrate a good safety profile supporting clinical development. Multiple vaccines for the novel coronavirus (COVID-19) are expected to complete preclinical research in April and enter clinical trials in China, NMPA officials declared at a press conference on March 17, 2020.

In response to the outbreak of coronavirus (COVID-19), JOINN assembled a team of internal experts to develop study designs tailored to evaluate different types of novel therapies against COVID-19. We have established clinical sample analysis centers in Wuhan to support clinical trials. JOINN participated in the safety assessment of most anti-SARS-CoV-2 drugs in China, including DNA vaccines, mRNA vaccines, recombinant protein-based vaccines, peptide vaccines, inactivated virus vaccines and other drugs such as antibodies, stem-cell therapy drugs, etc. Most drugs are still in the pre-clinical stage, some have already been submitted to the regulatory department of the NMPA (National Medical Products Administration) of China.


Founded in 1995, JOINN Laboratories (JOINN, SH603127) is China’s first private nonclinical CRO. JOINN subsidiaries are located in Beijing, Suzhou, Chongqing, and Wuzhou (GuangXi Province) in China, and Richmond (CA) and Worcester (MA) in the United States. JOINN is CNAS/ILAC-MRA accredited (China National Accreditation Service for Conformity Assessment/International Laboratory Accreditation Cooperation-Mutual Recognition Arrangement), AAALAC accredited (Association for Assessment & Accreditation of Lab Animal Care International) and OLAW accredited, and is NMPA (CFDA), US FDA, OECD and Ko-rean MFDS GLP certified/inspected/compliant. JOINN employs 1500+ pharmaceutical professionals and provides services from early-stage R&D to clinical trials and to post-approval pharmacovigilance, tailored to the sponsor’s needs.

JOINN has extensive experience on anti-virus drug safety assessment. We have participated in the drug R & D and safety assessment of SARS, H5N1, H1N1, H7N9 and Ebola virus. In response to the outbreak of coronavirus (COVID-19), JOINN developed a green channel for rapid response to antivirus non-clinical and clinical requests. We can help sponsors to communicate with local regulatory authorities, accelerating antivirus therapy development.

For the full report with language translation, see here.